Charles Wykoff MD PhD
Retinal Consultants of Houston
(713) 524-3434

Presentation: A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion